
USD
$0.00
(0.00%
)At Close (As of Oct 23, 2025)
$61.98B
Market Cap
14.73
P/E Ratio
39.7
EPS
$939.80
52 Week High
$475.77
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $12B |
| Total Revenue | $14B |
| Cost Of Revenue | $2.5B |
| Costof Goods And Services Sold | $2.5B |
| Operating Income | $4.2B |
| Selling General And Administrative | $3B |
| Research And Development | $4.6B |
| Operating Expenses | $7.6B |
| Investment Income Net | - |
| Net Interest Income | $656M |
| Interest Income | $711M |
| Interest Expense | $55M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $483M |
| Income Before Tax | $4.8B |
| Income Tax Expense | $367M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $4.4B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4.8B |
| Ebitda | $5.3B |
| Net Income | $4.4B |
| Field | Value (USD) |
|---|---|
| Total Assets | $38B |
| Total Current Assets | $19B |
| Cash And Cash Equivalents At Carrying Value | $2.5B |
| Cash And Short Term Investments | $2.5B |
| Inventory | $3.1B |
| Current Net Receivables | $6.2B |
| Total Non Current Assets | $19B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $1.1B |
| Intangible Assets Excluding Goodwill | $1.1B |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $8.9B |
| Short Term Investments | $6.5B |
| Other Current Assets | $349M |
| Other Non Current Assets | - |
| Total Liabilities | $8.4B |
| Total Current Liabilities | $3.9B |
| Current Accounts Payable | $790M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | $4.5B |
| Capital Lease Obligations | $720M |
| Long Term Debt | $2B |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $2.7B |
| Other Current Liabilities | $2.3B |
| Other Non Current Liabilities | $1.6B |
| Total Shareholder Equity | $29B |
| Treasury Stock | - |
| Retained Earnings | $32B |
| Common Stock | $100K |
| Common Stock Shares Outstanding | $115M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $4.4B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $483M |
| Capital Expenditures | $756M |
| Change In Receivables | - |
| Change In Inventory | -$620M |
| Profit Loss | - |
| Cashflow From Investment | -$2.5B |
| Cashflow From Financing | -$2.2B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$3.6B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $4.4B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $12B |
| Total Revenue | $14B |
| Cost Of Revenue | $2.5B |
| Costof Goods And Services Sold | $2.5B |
| Operating Income | $4.2B |
| Selling General And Administrative | $3B |
| Research And Development | $4.6B |
| Operating Expenses | $7.6B |
| Investment Income Net | - |
| Net Interest Income | $656M |
| Interest Income | $711M |
| Interest Expense | $55M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $483M |
| Income Before Tax | $4.8B |
| Income Tax Expense | $367M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $4.4B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4.8B |
| Ebitda | $5.3B |
| Net Income | $4.4B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-08-18 |
| Declaration Date | 2025-08-01 |
| Record Date | 2025-08-18 |
| Payment Date | 2025-09-03 |
| Amount | 0.88 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Regeneron Pharmaceuticals, Inc. is a prominent American biotechnology firm headquartered in Westchester County, New York, renowned for its pioneering research and development in monoclonal antibodies and therapeutic proteins. With a diverse portfolio that spans critical therapeutic areas such as oncology, ophthalmology, and immunology, Regeneron is celebrated for its flagship products, including Eylea and Dupixent. The company boasts a strong and innovative pipeline, reflecting its unwavering commitment to scientific excellence and its position as a major contributor to the biopharmaceutical sector, consistently delivering groundbreaking therapies to meet significant unmet medical needs.